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Background: The effects that artemether-lumefantrine (AL) has on gametocyte dynamics in the short-term have
recently been described. However there is limited long-term longitudinal data on the effect of AL on gametocyte
dynamics in asymptomatic children.
Methods: An epidemiological study was conducted in Kombewa, Western Kenya, in which 270 asymptomatic
children aged between 12 and 47 months were enrolled. The subjects were randomized to receive either a course
of AL or placebo at enrolment. Active follow-up was conducted for one year.
Results: The gametocyte prevalence and density dynamics throughout the study period mirrored that of the
asexual forms. The proportion of initially parasitaemic subjects becoming gametocytaemic was significantly lower
in the AL arm for the first 12 weeks following randomization. The geometric mean gametocyte density was lower
in the AL arm for 2 weeks following randomization. None of the variables of interest had a statistically significant
effect on the duration of gametocytaemia. There is no effect seen in subjects who are not parasitaemic at the
time of drug administration.
Conclusions: The treatment of asymptomatic parasitaemic subjects with AL results in a significant reduction in the
proportion of subjects who become gametocytaemic for at least 12 weeks.
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Epidemiological studyBackground
Both symptomatic and asymptomatic malaria infected
persons tend to harbour gametocytes, the sexual stage of
the malaria parasite that mediates its transmission from
the infected human host to a susceptible mosquito [1].
Because they are less likely to seek treatment, the
asymptomatic carriers constitute a significant reservoir
of parasites available for transmission by mosquitoes [2].* Correspondence: edwin.kamau@us.army.mil
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unless otherwise stated.The proportion of asymptomatic or subclinical Plasmo-
dium falciparum infections in endemic countries is high,
with microscopically detected prevalence reported to be
as high as 39% [3,4]. A large number of gametocyte
carriers have submicroscopic gametocytaemia [4,5].
Studies have shown that molecular methods detect
gametocytes 3- to 10-fold more than microscopy [6-8].
Interestingly, even at submicroscopic densities, game-
tocytes do infect mosquitoes and contribute to malaria
transmission [9,10].
Gametocyte carriage in naturally infected individuals
in a population is influenced by many factors such as
the age group [5,11-13], transmission settings [5,14,15],ral Ltd. This is an Open Access article distributed under the terms of the Creative
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[19-21]. Other important risk factors for gametocyte car-
riage include anaemia [22], durations of the infections,
recrudescent infections [23], fever [24], mixed infections
[23,25] and drug treatment [26,27].
Data on duration of gametocytes carriage in natural
infections is limited because such longitudinal studies
are challenging to conduct [5]. In a longitudinal study
conducted in 1958, volunteers were followed up for one
year, with sampling of the parasites done every other day
[28]. Eighty percent of the enrolled subjects had detect-
able gametocytes by microscopy at least once during fol-
low up, with more than half carrying gametocytes 20
times or more, and the longest duration of carriage was
estimated at 188 days. In another study, gametocyte
carriage was shown to extend to 30 days in Gambian
adults in a single transmission season [11]. In a study
conducted in western Kenya on asymptomatic children,
the mean duration of gametocyte carriage was shown to
decrease with increasing age [27]. This was a 30-day lon-
gitudinal study. Interestingly, children of < 10 years could
carry gametocytes for three weeks or more.
Treatment of asymptomatic asexual P. falciparum
carriers directly benefits the carriers given that the clear-
ance of the asexual parasite load prevents anaemia,
which in turn is associated with reduced work capacity,
poor pregnancy outcomes and reduced cognitive func-
tion [2]. Adoption of artemisinin‐based combination
therapy (ACT) as the first-line treatment of uncompli-
cated malaria has been beneficial because of their effect
on gametocytes and consequently malaria transmission
[29-32]. Artemether-lumefantrine (AL) is one of the
most widely used ACT in Africa with extensive efficacy
and safety data [2]. The effects that AL has on gameto-
cyte dynamics in the short-term have recently been
described [2,33]. However, there is limited long-term
longitudinal data on the effect that the administration of
AL to asymptomatic P. falciparum carriers has on gam-
etocyte dynamics. To describe this, data collected from a
longitudinal cohort study of the epidemiology of paediat-




Data was obtained from the longitudinal cohort study of
the epidemiology of paediatric malaria in Kombewa
Division, Western Kenya. The study was conducted in
order to estimate the prevalence of asymptomatic and
symptomatic malaria as well as to describe the temporal
pattern of episodes of symptomatic malaria among young
children living in Kombewa Division. An additional aim
was to assess whether administration of a curative dose of
an anti-malarial treatment at the beginning of the studyleads to a large change in the pattern of development of ep-
isodes of malaria during the subsequent follow-up period.
The information obtained from this study was for the plan-
ning and design of a paediatric malaria vaccine trial that
was to be conducted in the same area.
Study area
Kombewa Division is a 361 square kilometre rural area lo-
cated near Lake Victoria in the western part of Kenya, with
a population of approximately 70,000 and an under-five
population of approximately 8,500. The climate in
Kombewa is characterized by two rainy seasons – the
long rains (April through June) and the short rains
(August through October). The vegetation is largely sa-
vanna in nature. Kombewa has year round transmis-
sion of malaria, with the most intense transmission
occurring during the long rains and the short rains.
For the purpose of organizing recruitment and follow-
up of the volunteers, the field site was divided into 22
subdivisions. Within each subdivision in which a par-
ticipant resided there was a satellite field site that was
staffed 24 hrs/day, 7 days/week. Each household par-
ticipating in the study was thus located within a 1-mile
radius of a satellite field site that was accessible during
the rainy and dry seasons. The study protocol was
reviewed and approved by the Ethical Review Commit-
tee of the Kenya Medical Research Institute (KEMRI)
and the Human Use Review Committee of the Walter
Reed Army Institute of Research (WRAIR) and by the
Human Subjects Research and Review Board of the
Surgeon General of the US Army at Fort Detrick,
Maryland. Parents or guardians of participants were
provided written, informed consent before screening and
enrolment and had to pass an assessment of understanding.
Study design and procedures
This was an epidemiological follow-up study, in which a
total of 270 initially healthy, asymptomatic children aged
between 12 months and 47 months living within the
study area were enrolled in three age cohorts of 12–23
months, 24–35 months and 36–47 months. Inclusion
criteria included being 12 to 48 months of age, verifiable
by appropriate documentation. Subjects with clinical
signs of malaria and other significant medical conditions
such as homozygous sickle cell disease and malnutrition
were excluded. Samples for a baseline malaria blood film
(MBF) and a full blood count were collected just before
randomization; the results of MBF were not used to
determine eligibility, and were not made available to the in-
vestigators. The children were then randomized to receive
either a course of artemether-lumefantrine (Coartem®)
or placebo using a list prepared in advance using a
blocked randomization scheme. All study staff with the ex-
ception of the study pharmacists and the study coordinator
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pared by the study pharmacist at the clinic and its adminis-
tration directly supervised by study team members – the
first, third and fifth doses were administered at the clinic,
while the second, fourth and sixth doses were administered
by field workers at home. Each of the children was then
followed up for one year. The follow-up consisted of active
surveillance and passive surveillance. Active surveillance
consisted of weekly visits by field workers to the partici-
pants’ homes and scheduled monthly visits by the partici-
pants to the study clinic, during which samples for malaria
blood films were collected. Haemoglobin determination
was done during the monthly visit at the clinic. The results
of the MBFs collected during the active surveillance were
not availed to the investigators unless the subject was un-
well during a scheduled contact. Passive surveillance con-
sisted of unscheduled sick visits by the study participants to
the study clinic whenever the participants had specific com-
plaints – during these visits, laboratory assessments includ-
ing malaria blood films were done whenever the clinical
condition warranted. The results of the MBFs taken during
sick visits were made available to the investigators.
Subjects who were symptomatic and were diagnosed
with malaria as per the laboratory assessment during
the follow up period were treated with AL, regardless
of the randomization group.
Diagnosis of malaria
Duplicate thick and thin blood smears were made and
air dried. Thin blood smear was methanol fixed and
both smears were stained with 5% Giemsa in phosphate
buffer for 30 minutes. With high power objective the
smears were examined, the number, species and stage of
the parasites were recorded. The total numbers of para-
sites, both asexual and sexual forms per high power field
(HPF) were counted against 200 white blood cells. For
samples that had high density parasitaemia, the asexual
forms were counted against 2,000 red blood cells. A total
of 100 HPF were examined before a slide was considered
negative, and a minimum of 25HPF were examined on a
positive smear. Two independent microscopists exam-
ined the MBFs, and a mean of their findings calculated.
Discrepant results were resolved by having a third
reader, and the two closest results were taken. The micros-
copists were proficient and worked under the guidance of
malaria diagnostic centre within the programme.
Statistical analysis
All data were entered and verified in Microsoft Access
then imported into STATA software version 10 (Stata-
Corp., College Station, TX). Malaria parasite densities
were converted from parasites per 200 white blood cells
and parasites per 2,000 red blood cells to parasite/μL,
assuming a WBC count of 8000 or a RBC count of4×106 respectively. The duration of gametocytaemia was
calculated by assuming that a single gametocyte positive
slide represented gametocytes circulating in the periph-
eral blood for at least 2.5 days. If participants presented
with gametocyte positive MBFs on successive visits, the
duration of gametocytaemia was estimated as the inter-
val between the visits plus 2.5 days [34,35]. Covariates of
interest were the use of mosquito nets, age, presence of
mixed infection (P. falciparum and Plasmodium malariae,
or P. falciparum and Plasmodium ovale) and whether or
not the child was pre-treated with AL at randomization.
The baseline characteristics data is presented of the three
age groups; 12–23, 24–35 and 36–47 months in that order
respectively. The association between the time to the first
or only episode of gametocytaemia, as well as the risk for
multiple events of gametocytaemia, and the variables of
interest was analysed using Cox regression analysis. The as-
sociation between continuous outcomes (gametocyte dens-
ity, gametocytaemia duration) and the outcomes of interest
were evaluated using robust regression models.
Results
Study profile
A total of 539 children were screened, 270 met the eligi-
bility criteria and were enrolled into the study where 135
were randomized to receive placebo and 135 randomized
to receive AL. Of the 270 volunteers that were enrolled
into the study, 69% (187) completed the study which the
follow-up went on for a year. Of those that completed
the study, 53% (99 of 187) were in the placebo arm and
47% (88 of 187) in the AL arm. Of the 83 volunteers that
did not complete the one year follow-up, 81% (67) with-
drew their consent, with 55% (46 of 83) participants
citing their discomfort with the weekly blood draws as
the reason for consent withdrawal. Migration out of the
study area accounted for the remainder of those who did
not complete the study. No deaths were recorded among
the study cohort for the duration of the study. However,
two serious adverse events (SAEs) were recorded where
one child in the AL arm was hospitalized with a diagno-
sis of severe malaria 19 weeks after randomization - this
particular participant had defaulted on clinic visits, while
the other child in the placebo arm was hospitalized with
severe pneumonia. Both children recovered. All children
completed the six doses of the study treatment.
Baseline characteristics
The baseline characteristics of both treatment arms were
generally well balanced (Table 1). Insecticide-treated nets
(ITN) use was low in the study cohort (33% overall) with a
slight predominance in the placebo arm (36.3% versus.
29.6%). There was a general trend of higher ITN use in the
12–23 months age group than the older age groups (overall
43.3% versus 30.0% and 25.6%). Parasitological data for the
Table 1 Baseline characteristics
AL (N = 135) Placebo (N = 135) Overall (270)
Age in months – Mean (SD)a 29.6 (10.2) 30.1 (10.1) 29.8 (10.1)
Male – N (%) 72/135 (53.3) 69/135 (51.1) 141/270 (52.2)
Hb - Mean (SD) 9.9 (1.3) 9.9 (1.4) 9.9 (1.4)
Bed net use overall – N (%) 40/135 (29.6) 49/135 (36.3) 89/270 (33)
Bed net use 12–23 months – N (%) 16/45 (35.6) 23/45 (51.1) 39/45 (43.3)
Bed net use 24–35 months – N (%) 15/45 (33.3) 12/45 (26.7) 27/45 (30.0)
Bed net use 36–47 months – N (%) 9/45 (20.0) 14/45 (31.1) 23/45 (25.6)
aThe standard deviation (SD) from the mean of the sample size analysed.
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prevalence of parasitaemia at randomization was expectedly
high, considering that enrolment took place over a two-
week period between the end of May and early June, coin-
ciding with the peak of the malaria season (Table 2). A total
of 66.4% (176 of 265) participants had asexual parasitaemia
at randomization. The prevalence was lower in bed-net
users (58.1% versus 70.4%) and in the youngest age group
(52.0% versus 72.0% and 76.1%). Gametocyte prevalence at
enrolment was 17.4%, and was higher in bed net users
(23.3% versus 15.0%) and lower in the youngest age group
(16.0% versus 19.3% and 17.1%). The geometric mean
asexual parasite density at enrolment was 3328 p/μL
(IQR 940 – 12260) while the geometric mean gameto-
cyte density was 94.1 p/μL (IQR 40 – 120), with little
variation between the various groups.
Gametocyte prevalence and risk factors
The gametocyte prevalence dynamics throughout the
study period were similar to the asexual parasite preva-
lence dynamics, with the gametocyte prevalence peaks
coinciding with the asexual parasite prevalence peaks
(Figure 1). For subjects who had a positive MBF at
enrolment, the proportion of subjects who becameTable 2 Parasitological data at enrolment
N N (%)a
Overall 265 176/265 (66.4)
AL 133 92/133 (69.2)
Placebo 132 84/132 (64.0)
Bed net users 86 50/86 (58.1)
Bed net non users 179 126/179 (70.4)
Age 12–23 mo 89 46/89 (52.0)
Age 24–35 mo 88 63/88 (72.0)
Age 36–47 mo 88 67/88 (76.1)
Anemic 60 42/60 (70)
Not anemic 194 128/194 (66.0)
aAsexual parasite prevalence.
bAsexual parasite density (p/μL), Geometric mean (Inter Quartile Range [IQR]).
cGametocyte prevalence N (%).
dGametocyte density (p/μL), Geometric mean (Inter Quartile Range [IQR]).gametocytaemic was significantly lower for those who
received AL at randomization (24.6% versus. 50.7%,
P = 0.002). This effect was observed for the first
12 weeks following randomization (Figure 2). For sub-
jects who had a negative malaria smear at enrolment,
the difference in the proportion of subjects who be-
came gametocytaemic over the first 12 weeks in the
placebo and AL arms was not statistically significant (11.6%
versus 5.4% respectively, P = 0.326). Being in the older age
category, AL administration at randomization and bed net
use were protective against gametocytaemia, while being in
the second age category, having a positive smear at enrol-
ment and hyper-parasitaemia were significantly associated
with gametocytaemia (Table 3, P < 0.001 and P = 0.034). A
positive malaria smear at enrolment and mixed infection
were associated with faster appearance of the first or
only episode of gametocytaemia (Table 3, P = 0.016 and
P = 0.001). A positive smear for malaria at enrolment
and anaemia was statistically significantly associated
with the development of multiple events of gametocy-
taemia (Table 3, both events P < 0.001), while the second
age category, hyper-parasitaemia and mixed infection
seemed to reduce the risk for multiple events (Table 3,
P = 0.01 and P = 0.007).p/μL, (IQR)b N (%)c p/μL, (IQR)d
3328 (940,12260) 46/265 (17.4) 94.1 (40,120)
4016.0 (1180,1500) 31/133 (23.3) 102.0 (40,120)
2710.3 (860,10660) 15/132 (11.4) 80.0 (40,120)
2916.0 (880,10440) 20/86 (23.3) 112.0 (40,140)
3509.0 (960,13080) 26/179 (15.0) 83.0 (40,120)
3296.0 (840,14560) 14/89 (16) 100.0 (40,120)
3067.0 (720,10480) 17/88 (19.3) 101.0 (40,120)
3620.3 (1440,12480) 15/88 (17.1) 75.2 (40,120)
4373.3 (1760,13360) 8/60 (13.3) 115.4 (40,100)
3117.0 (780,12720) 37/194 (19.1) 92.2 (40,120)
Parasite prevalence
Weeks
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Figure 1 Gametocyte prevalence dynamics. Data showing the percent prevalence of asexual and sexual parasites throughout the study
period. The highest prevalence of asexual and sexual parasites was 66.4% and 17.4% respectively which was at the beginning of the study.
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Figure 2 Kaplan-Meier failure estimates showing the proportion of initially parasitaemic participants becoming gametocytaemic.
Participant who received AL at randomization had significantly lower gametocytes compared to placebo for the first 12 weeks.
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Table 3 Gametocyte risk factors
Variables Gametocytaemia versus variables First event versus variables Multiple events versus variables
OR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age category 2 1.05 (1.00, 1.11) 0.036 0.44 (0.16, 1.23) 0.118 0.63 (0.44, 0.89) 0.01
Age category 3 0.36 (0.17, 0.74) 0.005 0.75 (0.29, 1.90) 0.54 0.76 (0.54, 0.89) 0.01
Bed net use 0.26 (0.08, 0.91) 0.035 1.32 (0.57, 3.05) 0.515 1.34 (1.01, 1.80) 0.46
Pf enrolmenta 4.46 (2.94, 6.74) <0.001 3.36 (1.26, 8.98) 0.016 3.56 (2.37, 5.37) <0.001
Anaemia 1.24 (0.82, 1.88) 0.299 1.46 (0.55, 3.87) 0.447 2.06 (1.49, 2.85) <0.001
Hyper Pfb 1.44 (1.03, 2.01) 0.034 0.86 (0.20, 3.78) 0.845 0.34 (0.16, 0.74) 0.007
Pretreatment 1.81 (1.20, 2.72) 0.004 0.85 (0.38, 1.88) 0.682 0.81 (0.62, 1.06) 0.128
Mixed Infection 1.05 (1.00, 1.11) 0.036 4.89 (1.99, 11.99) 0.001 0.63 (0.44, 0.89) 0.01
aPlasmodium falciparum positive participants at enrolment.
bParticipants with hyper parasitaemia which is 100,000 p/mL and above.
Odds ratio (OR), hazardous ratio (HR), the 95% confidence interval (95% CI) and p-values based on Cox regression analysis were generated. Association between
gametocytaemia, the time to the first or only episode of gametocytaemia, the risk for multiple events of gametocytaemia, with the variables of interest
were determined.
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The gametocyte density dynamics were similar to the
asexual parasite density dynamics, with the peaks coin-
ciding with the asexual parasite density peaks (Figure 3).
The geometric mean density of asexual as well as sexual
forms of the parasite was lower in the AL arm for
2 weeks following randomization. However, the densities
actually surpassed those in the placebo arm after the
third week before they returned to levels similar to those
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Figure 3 The dynamics of sexual and asexual parasite density: shows
and placebo arms throughout the study.positively associated with asexual parasite density (Table 4,
P = 0.008) and negatively associated with haemoglobin
levels (Table 4, P < 0.001). The mean gametocytaemia
duration was 7.4 days (range 2.5 – 41.5) in the lowest
age category, 5.6 days (range 2.5 – 37.5) in the middle
age category and 6.2 days (range 2.5 – 44.5) in the
oldest age category. There was no statistically significant
difference in the gametocytaemia duration between the
age categories groups as determined by one-way ANOVA
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Figure 4 The dynamics of sexual and asexual parasite density: shows the dynamics of asexual and sexual parasite dynamics of both
AL and placebo arms in the first 12 weeks of randomization.
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fection versus those who did not (mean duration of 6.6
versus 6.3 days respectively, P = 0.8). None of the vari-
ables of interest had a statistically significant effect on
the duration of gametocytaemia in the regression model.
Discussion
This study presents longitudinal data on gametocytes
carriage in natural infections in a cohort of children
aged between 12 and 47 months old who were followed
for one year. The data shows that treatment of asymp-
tomatic parasitaemic subjects with AL results in a sig-
nificant reduction in the proportion of subjects who
become gametocytaemic for at least 12 weeks, despite
AL having a relatively short half-life. The half-life of
artemether is estimated to be 3.9 hrs and that of lume-
fantrine, the longer acting partner is estimated to beTable 4 Gametocyte density analysis
Variables Gametocyte density versus variables P value
Coef (95% CI)
Age −0.327 (−0.840, 0.185) 0.211
Parasitaemia 0.0000364 (9.33E-06, 6.36E-05) 0.008
Hb −8.009 (−12.355, −3.66334) <0.001
Mixed Infection −4.167 (−21.569, 13.236) 0.639
Age −0.388 (−0.896, 0.121) 0.135
Parasitaemia 3.29E-05 (6.65E-06, 5.91E-05) 0.014
Hb −7.995 (−12.389, −3.602) <0.001
Body Temp −0.874 (−4.399, 2.651) 0.627
Mixed Infection −2.480 (−20.443, 15.484) 0.787
Regression coefficient (Coef), the 95% confidence interval (95% CI) and p-values
based on robust regression model were generated. This analysis was used to asses
association between gametocyte density, which is a continuous outcome and the
outcomes of several variables as shown. Variables with and without body temp,
which has been speculated to affect gametocyte density were separated in
the analysis.32.7 hrs [36]. There was no effect seen in subjects who
were not parasitaemic at enrolment. Studies comparing
the risk of gametocyte carriage after treatment with AL
versus dihydroartemisinin-piperaquine (DP) have had
mixed results, with some studies showing no difference
[37,38], some showing increased risk after treatment
with AL [39,40] and DP [1,41-43]. Such differences
might be accounted for by the detection method used in
these studies and/or transmission intensity. Important
also might be whether the study subjects were parasitae-
mic or not at the time of drug administration, which
data here shows that this indeed matters. In a recent
study, Sawa et al., showed that AL had a more pro-
nounced effect on malaria transmission shortly after
treatment compared to DP [44]. This was the first study
to have directly determined gametocyte transmission to
mosquitoes that fed on post-treatment blood samples.
These authors speculated that AL may be the most
appropriate first-line choice for reducing community-
wide transmission of P. falciparum in setting of low en-
demicity. AL may be also a good candidate drug for mass
screening and treatment of malaria as well as Focal screen
and treat in the setting of high endemicity.
In line with other studies, the gametocyte prevalence dy-
namics throughout the study period followed closely that of
the asexual parasite [11,27]. The maximum gametocytae-
mia duration has been estimated at 22.2 days [40] using mi-
croscopy and 107.7 days [41] using molecular methods,
which was after non-ACT treatment of the subjects. The
maximum gametocytaemia duration in this study was
44.5 days. It is plausible that parasite density was submicro-
scopic on days when it was recorded as zero and much
longer gametocytes durations could have been estimated
using molecular methods. This study showed no evidence
of higher gametocyte density in the low malaria season as
had been suggested before [1]. In areas of high malaria
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lent in younger age groups, usually grouped as < 5 years old
[11,27]. In this study, there were no variations of gam-
etocyte prevalence between the age categories, further
supporting clustering of < 5 years age group together in
gametocyte prevalence analysis.
Having parasitaemia at enrolment and mixed infection
had a statistically significant influence on the time to the
occurrence of the first or only episode of gametocytaemia.
These findings are in line with what previous studies have
shown that mixed infection increases P. falciparum gam-
etocyte production [29,45]. Unlike the previous studies that
looked at co-infection with P. malariae only, the current
study looked at co-infection with both P. malariae and/or
P. ovale. Interestingly, being hyper parasitaemic or anaemic
did not have a statistically significant influence on the time
to the occurrence of the first or only event of gametocytae-
mia. Anaemia is considered to be a risk factor for gameto-
cytaemia [2]. Although many factors have been speculated
to be important in this relationship, cross-species immune
responses seem to be the most plausible because hyper-
parasitaemia or anaemia did not play a critical role. The
study data presented here support a phenomenon where
mixed infections trigger P. falciparum gametogenesis and
hence increased transmission potential. Mixed infections
therefore play an important role in prevalence and trans-
mission of falciparum malaria.
This study had three main limitations: First, while the
under-five age group was looked at exclusively, an im-
portant age category of this group - that of children aged
below 1 year - was not looked at. The contribution of
this age category in malaria transmission remains largely
unknown. Second, there is lack of parasite molecular
data that would have complemented the findings of
this study. This is in light of the knowledge that
sub-microscopic gametocytaemia plays a key role in
malaria transmission, and that 3–10 fold increase in
gametocyte carriage as determined by microscopy is seen
when molecular detection methods are used [4,6-8,46].
Lastly, the original study was designed to address a different
research question, and this may affect the statistical power
of this study.
Conclusion
This study provides key insights on the effect that treat-
ment of asymptomatic carriers on malaria transmission.
The treatment of asymptomatic parasitaemic subjects
with AL results in a significant reduction in the propor-
tion of subjects who become gametocytaemic for at least
12 weeks. There is no effect seen in subjects who are
not parasitaemic at the time of drug administration.
Competing interests
The authors declare that they have no competing interests.Authors’ contributions
BO was the study PI. BA, EK and BO conceived and executed the study (data
analysis). BA and JM analysed the data. BA, JM, EK wrote the manuscript. BO
reviewed the manuscript. All authors read and approved the final manuscript.
Acknowledgements
We would like to thank the study participants and their parents, the study
team in Kombewa, COL Gray Heppner (WRAIR) and Dr. Carter Diggs (USAID)
for their participation and support that they provided to this study. The
opinions and assertions contained herein are the private opinions of the
authors and are not to be construed as reflecting the views of the US
Army Medical Research Unit-Kenya or the US Department of Defense.
Funding
This study was supported by the USAID and Global Emerging Infections
Surveillance and Response System (GEIS), a division at the Armed Forces
Health Surveillance Center (AFHSC). The funders had no role in study design,
data collection and analysis decision to publish, or preparation of the
manuscript.
Received: 17 January 2014 Accepted: 5 July 2014
Published: 9 July 2014
References
1. Bousema T, Drakeley C: Epidemiology and infectivity of Plasmodium
falciparum and Plasmodium vivax gametocytes in relation to malaria
control and elimination. Clin Microbiol Rev 2011, 24:377–410.
2. Ogutu B, Tiono AB, Makanga M, Premji Z, Gbadoe AD, Ubben D, Marrast AC,
Gaye O: Treatment of asymptomatic carriers with artemether-
lumefantrine: an opportunity to reduce the burden of malaria? Malar J
2010, 9:30.
3. Mabunda S, Aponte JJ, Tiago A, Alonso P: A country-wide malaria survey
in Mozambique. II. Malaria attributable proportion of fever and establishment
of malaria case definition in children across different epidemiological settings.
Malar J 2009, 8:74.
4. Tiono A, Ouedraogo A, Ogutu B, Diarra A, Coulibaly S, Gansane A, Sirima S,
O’Neil G, Mukhopadhyay A, Hamed K: A controlled, parallel, cluster-randomized
trial of community-wide screening and treatment of asymptomatic carriers of
Plasmodium falciparum in Burkina Faso. Malar J 2013, 12:79.
5. Drakeley C, Sutherland C, Bousema JT, Sauerwein RW, Targett GA:
The epidemiology of Plasmodium falciparum gametocytes:
weapons of mass dispersion. Trends Parasitol 2006, 22:424–430.
6. Mens PF, Sawa P, van Amsterdam SM, Versteeg I, Omar SA, Schallig HD,
Kager PA: A randomized trial to monitor the efficacy and effectiveness
by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-
piperaquine for treatment and transmission control of uncomplicated
Plasmodium falciparum malaria in western Kenya. Malar J 2008, 7:237.
7. Schneider P, Bousema T, Omar S, Gouagna L, Sawa P, Schallig H, Sauerwein
R: (Sub)microscopic Plasmodium falciparum gametocytaemia in Kenyan
children after treatment with sulphadoxine-pyrimethamine monotherapy
or in combination with artesunate. Int J Parasitol 2006, 36:403–408.
8. Schneider P, Schoone G, Schallig H, Verhage D, Telgt D, Eling W, Sauerwein
R: Quantification of Plasmodium falciparum gametocytes in differential
stages of development by quantitative nucleic acid sequence-based
amplification. Mol Biochem Parasitol 2004, 137:35–41.
9. Ouedraogo AL, Bousema T, Schneider P, de Vlas SJ, Ilboudo-Sanogo E,
Cuzin-Ouattara N, Nebie I, Roeffen W, Verhave JP, Luty AJ, Sauerwein R:
Substantial contribution of submicroscopical Plasmodium falciparum
gametocyte carriage to the infectious reservoir in an area of seasonal
transmission. PLoS One 2009, 4:e8410.
10. Schneider P, Bousema JT, Gouagna LC, Otieno S, van de Vegte-Bolmer M,
Omar SA, Sauerwein RW: Submicroscopic Plasmodium falciparum gametocyte
densities frequently result in mosquito infection. Am J Trop Med Hyg 2007,
76:470–474.
11. Drakeley CJ, Akim NI, Sauerwein RW, Greenwood BM, Targett GA: Estimates
of the infectious reservoir of Plasmodium falciparum malaria in The
Gambia and in Tanzania. Trans R Soc Trop Med Hyg 2000, 94:472–476.
12. Githeko AK, Brandling-Bennett AD, Beier M, Atieli F, Owaga M, Collins FH:
The reservoir of Plasmodium falciparum malaria in a holoendemic area
of western Kenya. Trans R Soc Trop Med Hyg 1992, 86:355–358.
Andagalu et al. Malaria Journal 2014, 13:265 Page 9 of 9
http://www.malariajournal.com/content/13/1/26513. Mabunda S, Casimiro S, Quinto L, Alonso P: A country-wide malaria survey
in Mozambique. I. Plasmodium falciparum infection in children in
different epidemiological settings. Malar J 2008, 7:216.
14. Drakeley CJ, Carneiro I, Reyburn H, Malima R, Lusingu JP, Cox J, Theander
TG, Nkya WM, Lemnge MM, Riley EM: Altitude-dependent and
-independent variations in Plasmodium falciparum prevalence in
northeastern Tanzania. J Infect Dis 2005, 191:1589–1598.
15. Mwangi TW, Ross A, Snow RW, Marsh K: Case definitions of clinical malaria
under different transmission conditions in Kilifi District, Kenya. J Infect Dis
2005, 191:1932–1939.
16. Boudin C, Robert V, Verhave JP, Carnevale P, Ambroise-Thomas P: Plasmodium
falciparum and P. malariae epidemiology in a West African village. Bull World
Health Organ 1991, 69:199–205.
17. Oesterholt MJ, Bousema JT, Mwerinde OK, Harris C, Lushino P, Masokoto A,
Mwerinde H, Mosha FW, Drakeley CJ: Spatial and temporal variation in
malaria transmission in a low endemicity area in northern Tanzania.
Malar J 2006, 5:98.
18. Ouedraogo AL, de Vlas SJ, Nebie I, Ilboudo-Sanogo E, Bousema JT, Ouattara
AS, Verhave JP, Cuzin-Ouattara N, Sauerwein RW: Seasonal patterns of
Plasmodium falciparum gametocyte prevalence and density in a rural
population of Burkina Faso. Acta Trop 2008, 105:28–34.
19. Gouagna LC, Bancone G, Yao F, Yameogo B, Dabire KR, Costantini C,
Simpore J, Ouedraogo JB, Modiano D: Genetic variation in human HBB is
associated with Plasmodium falciparum transmission. Nat Genet 2010,
42:328–331.
20. Lawaly YR, Sakuntabhai A, Marrama L, Konate L, Phimpraphi W, Sokhna C,
Tall A, Sarr FD, Peerapittayamongkol C, Louicharoen C, Schneider BS,
Levescot A, Talman A, Casademont I, Menard D, Trape JF, Rogier C,
Kaewkunwal J, Sura T, Nuchprayoon I, Ariey F, Baril L, Singhasivanon P,
Mercereau-Puijalon O, Paul R: Heritability of the human infectious
reservoir of malaria parasites. PLoS One 2010, 5:e11358.
21. Paganotti GM, Palladino C, Modiano D, Sirima BS, Raberg L, Diarra A, Konate A,
Coluzzi M, Walliker D, Babiker HA: Genetic complexity and gametocyte
production of Plasmodium falciparum in Fulani and Mossi communities in
Burkina Faso. Parasitology 2006, 132:607–614.
22. von Seidlein L, Bojang K, Jones P, Jaffar S, Pinder M, Obaro S, Doherty T,
Haywood M, Snounou G, Gemperli B, Gathmann I, Royce C, McAdam K,
Greenwood B: A randomized controlled trial of artemether/benflumetol,
a new antimalarial and pyrimethamine/sulfadoxine in the treatment of
uncomplicated falciparum malaria in African children. Am J Trop Med Hyg
1998, 58:638–644.
23. Price R, Nosten F, Simpson JA, Luxemburger C, Phaipun L, ter Kuile F, van
Vugt M, Chongsuphajaisiddhi T, White NJ: Risk factors for gametocyte
carriage in uncomplicated falciparum malaria. Am J Trop Med Hyg 1999,
60:1019–1023.
24. Stepniewska K, Price RN, Sutherland CJ, Drakeley CJ, von Seidlein L, Nosten
F, White NJ: Plasmodium falciparum gametocyte dynamics in areas of
different malaria endemicity. Malar J 2008, 7:249.
25. Bousema JT, Drakeley CJ, Mens PF, Arens T, Houben R, Omar SA, Gouagna
LC, Schallig H, Sauerwein RW: Increased Plasmodium falciparum
gametocyte production in mixed infections with P. malariae. Am J Trop
Med Hyg 2008, 78:442–448.
26. Beavogui AH, Djimde AA, Gregson A, Toure AM, Dao A, Coulibaly B,
Ouologuem D, Fofana B, Sacko A, Tekete M, Kone A, Niare O, Wele M,
Plowe CV, Picot S, Doumbo OK: Low infectivity of Plasmodium falciparum
gametocytes to Anopheles gambiae following treatment with
sulfadoxine–pyrimethamine in Mali. Int J Parasitol 2010, 40:1213–1220.
27. Bousema JT, Gouagna LC, Drakeley CJ, Meutstege AM, Okech BA, Akim IN,
Beier JC, Githure JI, Sauerwein RW: Plasmodium falciparum gametocyte
carriage in asymptomatic children in western Kenya. Malar J 2004, 3:18.
28. Miller MJ: Observations on the natural history of malaria in the semi-
resistant West African. Trans R Soc Trop Med Hyg 1958, 52:152–168.
29. Barnes KI, Chanda P, Ab Barnabas G: Impact of the large-scale deployment
of artemether/lumefantrine on the malaria disease burden in Africa: case
studies of South Africa, Zambia and Ethiopia. Malar J 2009, 12:S8.
30. Barnes KI, Durrheim DN, Little F, Jackson A, Mehta U, Allen E, Dlamini SS,
Tsoka J, Bredenkamp B, Mthembu DJ, White NJ, Sharp BL: Effect of
artemether-lumefantrine policy and improved vector control on malaria
burden in KwaZulu-Natal South Africa. PLoS Med 2005, 2:e330.
31. Bhattarai A, Ali AS, Kachur SP, Martensson A, Abbas AK, Khatib R, Al-Mafazy
AW, Ramsan M, Rotllant G, Gerstenmaier JF, Molteni F, Abdulla S,Montgomery SM, Kaneko A, Björkman A: Impact of artemisinin-based
combination therapy and insecticide-treated nets on malaria burden in
Zanzibar. PLoS Med 2007, 4:e309.
32. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L,
Chongsuphajaisiddhi T, White NJ: Effects of artemisinin derivatives on
malaria transmissibility. Lancet 1996, 347:1654–1658.
33. Kakuru A, Jagannathan P, Arinaitwe E, Wanzira H, Muhindo M, Bigira V, Osilo E,
Homsy J, Kamya MR, Tappero JW, Dorsey G: The effects of ACT treatment and
TS prophylaxis on Plasmodium falciparum gametocytemia in a cohort of
young Ugandan children. Am J Trop Med Hyg 2013, 88:736–743.
34. Drakeley CJ, Flobbe K, Greenwood BM, Targett GA: Plasmodium falciparum
gametocytes in Gambian adults. Ann Trop Med Parasitol 2000, 94:399–401.
35. Smalley ME, Sinden RE: Plasmodium falciparum gametocytes: their
longevity and infectivity. Parasitology 1977, 74:1–8.
36. Mwesigwa J, Parikh S, McGee B, German P, Drysdale T, Kalyango JN, Clark
TD, Dorsey G, Lindegardh N, Annerberg A, Rosenthal PJ, Kamya MR, Aweeka
F: Pharmacokinetics of artemether-lumefantrine and artesunate-
amodiaquine in children in Kampala, Uganda. Antimicrob Agents
Chemother 2009, 54:52–59.
37. Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, Kalamya J,
Kamya MR, Vora N, Greenhouse B, Rosenthal PJ, Tappero J, Dorsey G:
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for
falciparum malaria: a longitudinal, randomized trial in young Ugandan
children. Clin Infect Dis 2009, 49:1629–1637.
38. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ,
Ouedraogo JB: Randomized comparison of amodiaquine plus
sulfadoxine-pyrimethamine, artemether-lumefantrine, and
dihydroartemisinin-piperaquine for the treatment of uncomplicated
Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 2007,
45:1453–1461.
39. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG,
Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F,
Dorsey G: Artemether-lumefantrine versus dihydroartemisinin-piperaquine for
treatment of malaria: a randomized trial. PLoS Clin Trials 2007, 2:e20.
40. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, Staedke SG,
Rosenthal PJ, Wabwire-Mangen F, Bukirwa H: Artemether-lumefantrine versus
dihydroartemisinin-piperaquine for treating uncomplicated malaria: a
randomized trial to guide policy in Uganda. PLoS One 2008, 3:e2390.
41. Tiburcio M, Silvestrini F, Bertuccini L, Sander AF, Turner L, Lavstsen T, Alano
P: Early gametocytes of the malaria parasite Plasmodium falciparum
specifically remodel the adhesive properties of infected erythrocyte
surface. Cell Microbiol 2012 http://dx.doi.org/10.1111/cmi.12062.
42. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menendez C, Nambozi
M, Valea I, Nabasumba C, Sasi P, Bacchieri A, Corsi M, Ubben D, Talisuna A,
D’Alessandro U: Dihydroartemisinin-piperaquine and artemether-lumefantrine
for treating uncomplicated malaria in African children: a randomised,
non-inferiority trial. PLoS One 2009, 4:e7871.
43. Nambozi M, Van Geertruyden JP, Hachizovu S, Chaponda M,
Mukwamataba D, Mulenga M, Ubben D, D’Alessandro U: Safety and
efficacy of dihydroartemisinin-piperaquine versus artemether-
lumefantrine in the treatment of uncomplicated Plasmodium
falciparum malaria in Zambian children. Malar J 2011, 10:50.
44. Sawa P, Shekalaghe SA, Drakeley CJ, Sutherland CJ, Mweresa CK, Baidjoe AY,
Manjurano A, Kavishe RA, Beshir KB, Yussuf RU, Omar SA, Hermsen CC, Okell
L, Schallig HD, Sauerwein RW, Hallett RL, Bousema T: Malaria transmission
after artemether-lumefantrine and dihydroartemisinin-piperaquine:
a randomized trial. J Infect Dis 2013, 207:1637–1645.
45. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F,
Ebsworth EP, Anstey NM, Tjitra E, Price RN: Two fixed-dose artemisinin
combinations for drug-resistant falciparum and vivax malaria in Papua,
Indonesia: an open-label randomised comparison. Lancet 2007, 369:757–765.
46. Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, Houben R,
Githure JI, Ord R, Sutherland CJ, Omar SA, Sauerwein RW: Moderate effect of
artemisinin-based combination therapy on transmission of Plasmodium
falciparum. J Infect Dis 2006, 193:1151–1159.
doi:10.1186/1475-2875-13-265
Cite this article as: Andagalu et al.: Longitudinal study on Plasmodium
falciparum gametocyte carriage following artemether-lumefantrine
administration in a cohort of children aged 12–47 months living in
Western Kenya, a high transmission area. Malaria Journal 2014 13:265.
